Skip to content

Optimizing the Radiological Selection and Transfer Model in Stroke Patients Presenting 6-24h After Onset (VESTA Study)

Treatment of Stroke in the Extended Window: Optimization of the Radiological Selection and Transfer Model in Patients With a Stroke Presenting 6-24h After Symptoms Onset (VESTA Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05299034
Acronym
VESTA
Enrollment
2173
Registered
2022-03-28
Start date
2022-01-14
Completion date
2023-08-15
Last updated
2023-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Ischemic

Brief summary

We aim to optimize the radiological selection and the transfer model in patients with a 6-24h stroke for a fairer and broader access to a reperfusion treatment. The specific objectives are: 1. To confirm that the selection of patients for reperfusion therapies in the late window is safe by applying the same clinical and imaging criteria recommended by clinical guidelines for the early window treatment selection. 2. To evaluate the performance of non-contrast CT by applying immediate post-processing software for the selection of patients for reperfusion treatment in the late window. 3. To analyze the prehospital and arrival variables at the primary stroke center to generate decision trees that optimize the transfer decision in patients with activation of the stroke code in \>6h from the onset of symptoms. METHODOLOGY: Study based on a mandatory, prospective, multicenter registry (CICAT registry) consisting of two phases 1. retrospective analysis with a detailed evaluation of the images of the included patients and generation of machine learning models that accurately predict the probability of receiving reperfusion treatment in the late window. 2. validation of the models in a prospective study. Clinical, radiological and transport variables will be studied. Response variables: rate of patients receiving reperfusion treatment in the late window, functional prognosis at 90 days, hemorrhagic transformation, and mortality.

Interventions

DIAGNOSTIC_TESTMultiparametric imaging

MR perfusion or multiparametric CT including NCCT, CTA and CTP

DIAGNOSTIC_TESTNon contrast CT+CT angiography

NCCT+CTA

Sponsors

Carlos III Health Institute
CollaboratorOTHER_GOV
Germans Trias i Pujol Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* SUBSTUDY 1. OPTIMIZATION OF IMAGING SELECTION METHODS FOR SELECTING STROKE PATIENTS FOR REPERFUSION TREATMENT IN THE EXTENDED WINDOW. \- Inclusion criteria: Consecutive patients registered in the CICAT registry between the years 2019 and 2021 with a stroke who meet the following criteria 1. Age older than 18 years, 2. Diagnosis of acute cerebral infarction, 3. More than six hours of evolution or uncertain chronology of symptoms, 4. Absence of disability prior to stroke (modified Rankin score 0-2), 5. NIHSS score\>5, 6. Neuroimaging study including at least one non-contrast cranial CT scan within 60 minutes of arrival at the hospital center. * SUBSTUDY 2. OPTIMIZATION OF CIRCUITS AND TRANSFER MODEL IN PATIENTS WITH STROKE IN THE EXTENDED WINDOW OF TREATMENT. * Inclusion criteria: Selection of consecutive, prospective patients to be included in the CICAT registry between January 2023 and March 2024 with stroke meeting the following criteria: 1. Age over 18 years, 2. Suspicion of acute cerebral infarction, 3. More than six hours of evolution or uncertain chronology of symptoms, 4. absence of pre-stroke disability (modified Rankin score 0-2), 5. NIHSS score greater than 5.

Design outcomes

Primary

MeasureTime frameDescription
mRS at 90 days90 days after strokePercentage of patients with functional independence, defined as mRS \< or =2 on day 90 as assessed centrally by blinded evaluators of the Catalan Stroke Master Plan.
Rate of patients treated with mechanical thrombectomyless than 24 hours after the diagnostic test

Secondary

MeasureTime frame
Mortality at discharge and at day 9090 days after stroke
Symptomatic intracerebral hemorrhage, defined as PH2 or SAH on imaging test at 24-72 hours associated with a worsening in NIHSS ≥ 4 pointsFrom 24 to 72 hours after stroke

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026